HEARTBiT: A Breakthrough Transcriptomic Biomarker for Early Detection of Acute Cellular Rejection Post-Heart Transplantation

Highlight

  • HEARTBiT, a blood-based transcriptomic biomarker, reliably detects moderate-to-severe acute cellular rejection (ACR) after heart transplantation across the first post-operative year.
  • The biomarker maintains high diagnostic accuracy early post-transplant (≤60 days) when rejection risk is greatest, showing an AUC of 0.78 and sensitivity up to 89%.
  • HEARTBiT enables safe reduction of invasive endomyocardial biopsies, sparing over 50% of routine surveillance biopsies without significantly increasing missed rejection cases.
  • Serial tracking of HEARTBiT scores demonstrates prognostic potential by rising weeks before histological biopsy detection of rejection, enabling earlier intervention possibilities.

Specialty calculators

Browse calculators

For clinical reference; use professional judgment.

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply